Composition, form of production and packaging
Suppositories rectal yellow with possible splashes of orange-yellow color, torpedo-shaped.
cocarboxylase hydrochloride 25 mg
riboflavin 2 mg
Thioctic (? -lipoic) acid 12 mg
Excipients: cocoa butter or solid fat.
5 pieces. - packings cellular planimetric (2) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2010.
The drug with fortifying effect. Combined drug, the effect of which is determined by the effects of its constituent vitamins and coenzymes, as well as synergies.
Cocarboxylase hydrochloride (coenzyme) catalyzes the carboxylation and decarboxylation of О±-keto acids, participates in the carbohydrate metabolism, through the participation in the pentose cycle mediates the synthesis of nucleic acids, proteins, lipids. Activates tissue metabolism. The drug is used for correction in metabolic acidosis, cellular hypoxia, other metabolic disorders, inadequate liver function, kidney function, cardiovascular system, chronic intoxication.
Riboflavin (vitamin B 2 ) as a coenzyme of flavinoproteins participates in the regulation of redox reactions, as well as in the processes of carbohydrate, protein and fat metabolism; plays an important role in the synthesis of hemoglobin and maintenance of normal visual function of the eye, the condition of the mucous membranes and skin.
Lipoic acid participates in the oxidative decarboxylation of pyruvic acid and ОІ-keto acids, in the regulation of lipid and carbohydrate metabolism, plays an important role in the process of the formation of energy in the body. Lipoic acid has a hepatoprotective effect, improves the detoxification function of the liver, protects against exposure to exo- and endotoxins.
Coripil improves tissue metabolism under various physiological and pathological conditions, requiring correction by cofactors and substrates.
Data on the pharmacokinetics of the drug Corilip are not available.
As a monotherapy or as an addition to basic therapy for various pathological conditions in children, including:
- chronic tissue hypoxia;
- decreased immunity;
- bacterial and viral infections;
- chronic somatic diseases;
- Chronic intoxications;
- conditions after severe illnesses;
- eating disorder (hypotrophy).
Periods of intensive growth and development of new functions in the child, with intense physical and mental stress, in stressful situations.
As a general restorative for prevention during the epidemic of infectious diseases.
The drug is used rectally. Having released from packing, it is necessary to enter a suppository into an anus (after preliminary emptying of an intestine).
The newborn and infants are prescribed 1/2 suppository / day; children aged 1 to 6 years) - 1 suppository / day; Children aged 6 to 14 years - 1-2 suppositories / day.
The duration of the course of treatment is 10 days. The total duration of treatment is 3-4 courses with an interval of 20 days (3-4 months).
Allergic reactions: rarely - hives, itching, bronchospasm, dyspepsia.
If adverse reactions occur, the patient should stop taking the drug and consult a doctor.
- Hypersensitivity to the components of the drug.
APPLICATION FOR CHILDREN
The drug is intended for use in children.
Criteria for the duration of treatment along with the clinical status are the cytochemical indices of the activity of peripheral blood leukocyte enzymes (succinate dehydrogenase and glycerophosphate dehydrogenase).
Data on the overdose of the drug Corilip not provided.
Negative interaction was not observed.
The drug can be used for complex therapy.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children, protected from light at a temperature of no higher than 9 В° C. Shelf life - 2 years.